Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Patent
1995-06-06
1998-11-24
Caputa, Anthony C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
435325, 435366, 435371, 530828, A61K 3900
Patent
active
058403175
ABSTRACT:
A new polyvalent melanoma cell vaccine is disclosed comprised of one or more allogeneic melanoma cell lines which contain effective concentrations of melanoma associated antigens. Further disclosed are a method of stimulating an immunological response by administering the described vaccine as well as a method of prognosticating a patient.
REFERENCES:
patent: 4233286 (1980-11-01), Soothill et al.
patent: 4557931 (1985-12-01), Irie et al.
patent: 4562160 (1985-12-01), Real et al.
patent: 5030621 (1991-07-01), Bystryn
patent: 5194384 (1993-03-01), Bystryn
patent: 5427664 (1995-06-01), Stoev et al.
Gupta et al. JNCI 70(6): 993-1004 1983.
Gupta et al. JNCI 63(2): 347-56 1979.
Gupta et al. JNCI 72(1): 75-82 1984.
J. Biol. Chem 262(14): 6803-17 1987.
Melanoma Vaccines (Chapter 42) In: Cutaneous Melanoma,C.M. Balch and A.N. Houghton, Eds., publ. J.B. Lippincott Compamy PA., 542-559. 1991.
Euhus et al., "A Murine Monoclonal Antibody to a Glycoprotein Tumor Associated Antigen in Sera and Urine of Melanoma Patients," Immunology, Proceedings of AACR, Abstract, 29:393, Mar. 1988.
Euhus et al., "Demonstration and Isolation of a Glycoprotein Tumor Associated Antigen from Sera of Melanoma Patients," Biomarkers and Diagnosis, Proceedings of ASCO, Abstract, 7:44, Mar. 1988.
Euhus et al., "Effects of Melanoma Cell Vaccine on Levels of Antibody to a Tumor Associated Antigen in Melanoma Patients," In Proceedings of American Association for Cancer Research, 1987.
Euhus et al., "Measurement of a Glycoprotein Tumor Associated Antigen (TAA) Using Antibodies of Different Isotypes from a Melanoma Patient," 1988 FASEB Abstract Form.
Foshag et al., "T-Cell Cytotoxicity in Melanoma Patients Receiving Active Specific Immunotherapy (ASI) and Correlation to Clinical Outcome," Oncology, 430-431.
Foshag et al., "Specific cell mediated cytotoxicity in Melanoma Patients Receiving Melanoma Cell Vaccine (MCV) in Combination with Various Biological Response Modifiers (BRM)," Proceedings of the American Association for Cancer Research, 30:344, Mar. 1989.
Gupta and Morton, "Detection of Cancer-Associated Antigen(s) in Urine of Sarcoma Patients," Journal of Surgical Oncology, 11:65-74, 1979.
Gupta and Morton, "Immunochemical Characterization of Fetal Antigen Isolated From Spent Medium of a Human Melanoma Cell Line," JNCI, 70(6):993-1004, Jun. 1983.
Gupta and Morton, "Monoclonal Antibody-Based ELISA to Detect Glycoprotein Tumor-Associated-Antigen-Specific Immune Complexes in Cancer Patients," Journal of Clinical Laboratory Analysis, 6:329-336, 1992.
Gupta and Morton, "Studies of a Melanoma Tumor-Associated Antigen Detected in the Spent Culture Medium of a Human Melanoma Cell Line by Allogeneic Antibody. I. Purification and Development of a Radioimmunoassay," JNCI, 72(1):67-74, Jan. 1984.
Gupta et al., "Correlation of Humoral Immune Response to a Melanoma Tumor Associated Antigen with Survival of Melanoma Patients Receiving Active Specific Immunotherapy," Proceedings of the American Association for Cancer Research, ABSTRACT 30:344, Mar. 1989.
Gupta et al., "Demonstration of Two Distinct Antigens in Spent Tissue Culture Medium of a Human Malignant Melanoma Cell Line," JNCI, 63(2):347-356, Aug. 1979.
Gupta et al., "Detection of Tumor Associated Antigen in Urine of Melanoma Patients by Allogeneic Antibody," FASEB Abstract Form, Apr. 1987.
Gupta et al., "Increase in Antibody Level to a Tumor Associated Antigens in Melanoma Patients Undergoing Immunotherapy with a Tumor Cell Vaccine," Immunology and Cytokines, Proceedings of ASCO, 6:249, Mar. 1987.
Hoon et al., "A Prospective Randomized Trial of Immunomodulation with Low Dose Cyclophosphamide (CYP) in Patients Receiving Active Specific Immunotherapy with Melanoma Cell Vaccine (MCV)," Melanoma, Proceedings of ASCO, 6:212, Mar. 1987.
Hoon et al., "A Randomized Trial of Immunomodulation with Various Low Dosages of Cyclophosphamide in Patients Receiving Active Specific Immunotherapy with Melanoma Cell Vaccine," Immunology, Proceedings of AACR, 29:413, Mar. 1988.
Hoon et al., "Mixed Lymphocyte-Tumor Reaction and Delayed Type Hypersensitivity in Patients Receiving Specific Immunotherapy," Immunology,Proceedings of the American Association for Cancer Research, 31:253, Mar. 1990.
Hoon et al., "Suppressor Cell Activity in a Randomized Trial of Patients Receiving Active Specific Immunotherapy with Melanoma Cell Vaccine and Low Dosages of Cyclophosphamide," Cancer Research, 50:5358-5364, Sep. 1990.
Huth et al., "Relationship of Tumor-Associated Urinary Antigens to Disease Recurrence in Melanoma Patients," Surgical Oncology, 417-419. 1985.
Irie et al., "Antibodies to Tumor-Associated Gangliosides (GM2 and GD2): Potential for Suppression of Melanoma Recurrence," In: Basic Mechanisms and Clinical Treatment of Tumor Metastasis, Chapter 21, pp. 371-383, 1985.
Irie et al., "Human Monoclonal Antibody to Ganglioside GM2 for Melanoma Treatment," The Lancet, pp. 786-787, Apr. 1989.
Irie et al. "Humoral Immune Response to Melanoma-Associated Membrane Antigen and Fetal Brain Antigen Demonstrated by Indirect Membrane Immunofluorescence. I," Cancer Immunol. Immunother., 6:33-39, 1979.
Irie et al., "Oncofetal Antigen: A Tumor-Associated Fetal Antigen Immunogenic in Man," JNCI, 63(2):367-373, Aug. 1979.
Kopald et al., "Complement Dependent Cytotoxicity Against Tumor Cell Lines by a Purified Baboon IgM Antibody to a Tumor Associated Antigen," Immunology, Proceedings of the American Association for Cancer Research, 30:346, Mar. 1989.
Morton, "Active Immunotherapy Against Cancer: Present Status," Seminars in Oncology, 13(2):180-185, Jun. 1986.
Morton, "Adjuvant Immunotherapy of Malignant Melanoma: Status of Clinical Trials at UCLA," Int. J. Immunotherapy, II(1):31-36, 1986.
Morton et al., "Active Immunotherapy of Metastatic Melanoma with Melanoma Vaccine and Immunomodulation," Extended Abstracts, Proceedings of the American Associated for Cancer Research, 32:492-494, Mar. 1991.
Morton et al., "Active Specific Immunotherapy of Malignant Melanoma," Chapter 13, pp. 152-161. 1989.
Morton et al., "Active Specific Immunotherapy in Malignant Melanoma," Seminars in Surgical Oncology, 5:420-425, 1989.
Morton et al., "Active Specific Immunotherapy with Melanoma Cell Vaccine and Immunomodulation in Patients with Metastatic Melanoma," May 19-21, 1991 ASCO Abstract of ASCO Annual Meeting.
Morton et al., "Active Specific Immunotherapy with Melanoma Cell Vaccine and Immunomodulation in Patients with Metastatic Melanoma," Abstract of Presentation at the International Conference on Biological Treatment of Melanoma and Other Cancers, New South Wales, Sep. 5-7, 1990.
Morton et al., "Adjuvant Immunotherapy of Malignant Melanoma: Results of a Randomized Trial in Patients with Lymph Node Metastases," Section VI. Melanoma, pp. 245-249, 1982.
Morton et al., "Clinical Results of a Trial of Active Specific Immunotherapy with Melanoma Cell Vaccine and Immunomodulation in Metastatic Melanoma," Immunology, Proceedings of the American Association for Cancer Research, 30:383, Mar. 1989.
Morton et al., "Clinical Results of a Trial of Immunotherapy with Melanoma Cell Vaccine (MCV) Plus Biological Response Modifiers," Jul. 30-Aug. 5, 1989, Abstract 7th International Congress Immunology, Berlin.
Morton et al., "Immunological Factors Which Influence Response to Immunotherapy in Malignant Melanoma," Surgery, 68(1):158-164, Jul. 1970.
Morton et al., "Improved Survival of Patients with Metastatic Melanoma (MM) Receiving Active Immunotherapy," American Surgical Association, p. 83, 1992.
Morton et al., "Long-Term Survival in Metastatic Melanoma After Active Immunotherapy with Melanoma Cell Vaccine and Immunomodulation," Immunology, Proceedings of the American Association for Cancer Research," 31:281, Mar. 1990.
Morton et al., "Preliminary Results of a Randomized Trial of Adjuvant Immunotherapy in Patients with Malignant Melanoma Who Have Lymph Node Metastases," Aust. NZ, J. Surg., 48(1):49-52, Feb. 1978.
Morton et al., "Treatment of Malignant Melanoma by Active Specific Immunotherapy in Combination with Biological Response Modifiers," pp. 665-6
LandOfFree
Composition comprising tumor cell lines containing GD2 gangliosi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition comprising tumor cell lines containing GD2 gangliosi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition comprising tumor cell lines containing GD2 gangliosi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1699333